ABSTRACT
HLA-C*07:01:126 differs from HLA-C*07:01:01:01 by one nucleotide substitution in codon 328 in exon 7.
Subject(s)
Alleles , Base Sequence , Exons , HLA-C Antigens , Histocompatibility Testing , Sequence Analysis, DNA , Humans , HLA-C Antigens/genetics , Histocompatibility Testing/methods , Sequence Analysis, DNA/methods , Codon , Sequence AlignmentABSTRACT
HLA-A*24:02:169 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon -23 in exon 1.
Subject(s)
Alleles , Base Sequence , Exons , HLA-A24 Antigen , Histocompatibility Testing , Sequence Analysis, DNA , Humans , Histocompatibility Testing/methods , HLA-A24 Antigen/genetics , HLA-A24 Antigen/immunology , Sequence Analysis, DNA/methods , Codon , Sequence Alignment , Polymorphism, Single NucleotideABSTRACT
HLA-C*01:262 differs from HLA-C*01:02:01:01 by one nucleotide substitution in codon 150 in exon 3.
Subject(s)
Alleles , Base Sequence , Codon , Exons , HLA-C Antigens , Histocompatibility Testing , Sequence Analysis, DNA , Humans , Histocompatibility Testing/methods , HLA-C Antigens/genetics , Polymorphism, Single Nucleotide , Sequence Alignment , Sequence Analysis, DNA/methodsABSTRACT
HLA-A*26:247 differs from HLA-A*26:01:01:01 by one nucleotide substitution in codon 245 in exon 4.
Subject(s)
Alleles , Base Sequence , Exons , HLA-A Antigens , Histocompatibility Testing , Sequence Analysis, DNA , Humans , Codon , Histocompatibility Testing/methods , HLA-A Antigens/genetics , Sequence Alignment , Sequence Analysis, DNA/methodsABSTRACT
HLA-B*51:411 differs from HLA-B*51:01:01:01 by one nucleotide substitution in codon 235 in exon 4.
Subject(s)
Alleles , Base Sequence , Exons , Sequence Analysis, DNA , Humans , Codon , HLA-B Antigens/genetics , Sequence Alignment , Sequence Analysis, DNA/methodsABSTRACT
HLA-DPB1*1618:01 differs from HLA-DPB1*18:01:01:01 by one nucleotide substitution in codon 215 in exon 4.
Subject(s)
Alleles , Base Sequence , HLA-DP beta-Chains , Sequence Analysis, DNA , Humans , HLA-DP beta-Chains/genetics , Sequence Analysis, DNA/methodsSubject(s)
Allografts , Kidney Transplantation , Adult , Female , Humans , Male , Middle Aged , Allografts/immunology , Allografts/pathology , Autoantibodies/blood , Autoantibodies/immunology , Kidney Transplantation/adverse effects , Membrane Proteins/immunology , Podocytes/immunology , Podocytes/pathology , RecurrenceABSTRACT
HLA-DRB1*08:126 differs from HLA-DRB1*08:04:01:01 by one nucleotide substitution in codon 152 in exon 3.
Subject(s)
Alleles , Base Sequence , Exons , HLA-DRB1 Chains , Histocompatibility Testing , Sequence Analysis, DNA , Humans , HLA-DRB1 Chains/genetics , Histocompatibility Testing/methods , Sequence Analysis, DNA/methods , Codon , Sequence AlignmentABSTRACT
HLA-C*07:02:151 differs from HLA-C*07:02:01:01 by one nucleotide substitution in codon 166 in exon 3.
Subject(s)
Alleles , Base Sequence , Codon , Exons , HLA-C Antigens , Histocompatibility Testing , Sequence Analysis, DNA , Humans , HLA-C Antigens/genetics , Histocompatibility Testing/methods , Sequence Analysis, DNA/methods , Sequence AlignmentABSTRACT
BACKGROUND: APECED syndrome is a rare disease caused by biallelic mutations of the AIRE gene, usually presenting with the triad "hypoparathyroidism-adrenal failure-chronic mucocutaneous candidiasis (CMC)" and non-endocrine manifestations. The aim of this study was to determine the molecular profile of the AIRE gene, the prevalence of rare manifestations and to characterize immunological disturbances in a French cohort. PATIENTS AND METHODS: A national, multicenter prospective observational study to collect genetic, clinical, biological and immunological data (NCT03751683). RESULTS: 25 patients (23 families) were enrolled. Eleven distinct AIRE variants were identified, two of which were not previously reported: an intronic variant, c.653-70G > A, and a c.1066del (p.Arg356GlyfsX22) variant (exon 9). The most common was the Finnish variant c.769C > T (16 alleles), followed by the variant c.967_979del13 (15 alleles), which seemed associated with a less severe phenotype. 17/25 patients were homozygote. The median number of clinical manifestations was seven; 19/25 patients presented with the hypoparathyroidism-adrenal failure-CMC triad, 8/13 showed pulmonary involvement, 20/25 had ectodermal dystrophy, 8/25 had malabsorption, and 6/23 had asplenia. Fifteen out of 19 patients had NK cell lymphopenia with an increase in CD4+ and CD8+ T lymphocytes and an age-dependent alteration of B lymphocyte homeostasis compared with matched controls (p < 0.001), related to the severity of the disease. All tested sera (n = 18) were positive for anti-interferon-α, 15/18 for anti-interleukin-22 antibodies, and 13/18 for anti-interleukin-17F antibodies, without clear phenotypic correlation other than with CMC. CONCLUSION: This first prospective cohort showed a high AIRE genotype variability, with two new gene variants. The prevalence of potentially life-threatening non-endocrine manifestations, was higher with systematic screening. These manifestations could, along with age-dependent B-cell lymphopenia, contribute to disease severity. Systematic screening for all the manifestations of the syndrome would allow earlier diagnosis, supporting vaccination, and targeted therapeutic approaches.
ABSTRACT
HLA-B*14:121 differs from HLA-B*14:01:01:01 by one nucleotide substitution in codon 319 in exon 6.
Subject(s)
Genes, MHC Class I , HLA-B Antigens , Humans , Alleles , Histocompatibility Testing , Codon , HLA-B Antigens/genetics , Sequence Analysis, DNAABSTRACT
HLA-C*05:286 differs from HLA-C*05:01:01:02 by one nucleotide substitution in codon 283 in exon 5.
Subject(s)
Genes, MHC Class I , HLA-C Antigens , Humans , HLA-C Antigens/genetics , Alleles , Histocompatibility Testing , Codon , Sequence Analysis, DNAABSTRACT
HLA-B*51:394Q differs from HLA-B*51:01:01:05 by one nucleotide substitution in codon 339 in exon 7.
Subject(s)
HLA-B Antigens , Humans , Alleles , Histocompatibility Testing , Codon , HLA-B Antigens/genetics , Sequence Analysis, DNAABSTRACT
HLA-C*01:263 differs from HLA-C*01:02:01:01 by one nucleotide substitution in codon 98 in exon 3.
Subject(s)
Genes, MHC Class I , HLA-C Antigens , Humans , HLA-C Antigens/genetics , Alleles , Histocompatibility Testing , Codon , Sequence Analysis, DNAABSTRACT
HLA-B*40:539 differs from HLA-B*40:01:01 by one nucleotide substitution in codon 46 in exon 2.
Subject(s)
Genes, MHC Class I , HLA-B Antigens , Humans , Alleles , Histocompatibility Testing , Codon , HLA-B Antigens/genetics , Sequence Analysis, DNAABSTRACT
HLA-C*06:176:02 differs from HLA-C*06:176:01 by two nucleotide substitutions in codons 236 and 237 in exon 4.
Subject(s)
Genes, MHC Class I , HLA-C Antigens , Humans , HLA-C Antigens/genetics , Alleles , Histocompatibility Testing , Exons/genetics , Sequence Analysis, DNAABSTRACT
Given the risk of rejection, the presence of preformed donor specific antibodies (DSA) contraindicates transplantation in most allocation systems. However, HLA-Cw and -DP DSA escape this censorship. We performed a multicentric observational study, in which the objective was to determinate risk factors of acute antibody-mediated rejection (aABMR) in recipients transplanted with preformed isolated Cw- or DP-DSA. Between 2010 and 2019, 183 patients were transplanted with a preformed isolated Cw- or DP-DSA (92 Cw-DSA; 91 DP-DSA). At 2 years, the incidence of aABMR was 12% in the Cw-DSA group, versus 28% in the DP-DSA group. Using multivariable Cox regression model, the presence of a preformed DP-DSA was associated with an increased risk of aABMR (HR = 2.32 [1.21-4.45 (p = 0.001)]) compared with Cw-DSA. We also observed a significant association between the DSA's MFI on the day of transplant and the risk of aABMR (HR = 1.09 [1.08-1.18], p = 0.032), whatever the DSA was. Interaction term analysis found an increased risk of aABMR in the DP-DSA group compared with Cw-DSA, but only for MFI below 3,000. These results may plead for taking these antibodies into account in the allocation algorithms, in the same way as other DSA.
Subject(s)
Kidney Transplantation , Humans , Antibodies , Graft Rejection , Graft Survival , Histocompatibility Testing , HLA Antigens , Kidney Transplantation/adverse effects , Tissue DonorsABSTRACT
HLA-DPB1*1463:01N differs from HLA-DPB1*02:01:02:04 by one nucleotide substitution in codon 128 in exon 3.
Subject(s)
Base Sequence , Humans , Alleles , HLA-DP beta-Chains/genetics , Codon , Sequence Analysis, DNAABSTRACT
HLA-B*44:324:02 differs from HLA-B*44:324:01 by one nucleotide substitution in codon 99 in exon 3.
Subject(s)
HLA-B Antigens , Humans , Alleles , Histocompatibility Testing , Codon , Sequence Analysis, DNAABSTRACT
HLA-C*12:384 differs from HLA-C*12:03:01:02 by one nucleotide substitution in codon 42 in exon 2.